US regulator moved to end bulk compounding of GLP-1s
The FDA proposed formally excluding semaglutide, tirzepatide and liraglutide from the list of bulk substances that outsourcing facilities may compound, on the basis that there is no clinical need. This is a US matter with no direct UK effect, but compounded product from US sources has been a route into the UK grey market.
Sources
What this is. A dated, sourced note on something that changed. Peptide Register is an independent reference: it sells nothing, carries no advertising, and takes no money from any company selling any compound it covers. This is not medical advice. If a change affects a medicine you are prescribed, speak to your doctor or pharmacist rather than acting on something you read here.